Ophthalmology Advisor20h
GLP-1RA Drugs May Reduce The Risk of Glaucoma in Patients Without Diabetes
Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.
Pharmaceutical Technology13h
ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesity
GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.
Costly GLP-1 drug use for weight loss has soared, study reports
The number of Americans taking cutting-edge weight-loss drugs like Ozempic, Wegovy and Zepbound has skyrocketed in recent ...
Becker's Hospital Review14h
GLP-1 spending hits $5.8B for adults without diabetes
A new study found that spending on GLP-1 medications such as Ozempic, Wegovy and Zepbound surged to $5.8 billion in 2022 ...
Pharmaceutical Commerce23h
The Financial Barrier to GLP-1s
In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirst’s chief ...